CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for A.C.N. 167 748 843 Limited (In Liquidation) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

A.C.N. 167 748 843 Limited (In Liquidation)
L 9 85 Castlereagh Street
Phone: +61 282395400p:+61 282395400 SYDNEY, NSW  2000  Australia Fax: +61 283629547f:+61 283629547
Placed into Administration on 3/10/2022
On 3/10/2022, Farmaforce Ltd was placed into Voluntary Administration. The Company's Board of Directors appointed Mark Robinson, Anthony Resnick, and Riad Tayeh of de Vries Tayeh as the Joint Administrators of the Company pursuant to section 436A of the Corporations Act 2001.
On 7/11/2022, the creditors of A.C.N. 167 748 843 Ltd (f/k/a Farmaforce Limited) voted to place the Company into Liquidation. Mark Robinson was appointed as the Liquidator of the Company.
This company is no longer actively traded on any major stock exchange.
Business Summary
A.C.N. 167 748 843 Limited, formerly Farmaforce Limited, is an Australia-based company, which provides sales, data and medical affairs solutions to the healthcare industry. The Company also provides scalable, customized solutions on demand to its clients. The Company operates through two segments: contract sales and marketing services to external customers, and services to related parties. The Company’s data intelligence services include market surveys, geo-mapping, market analysis and sales force analytics. The Company’s medical affairs solutions include various services, such as medical science liaisons (MSLs) teams and solutions to meet client’s business goals, medical information service for timely response to product related enquiries, pharmacovigilance operations (PV) that ensure compliance with local PV/ product safety regulations. Its medical affairs product pre-launch planning and implementation focused on client’s product launch needs and readiness.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20216/30/2021Yes----

Industries
SIC Code Description
8742 Management consulting services
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board VincenzoMilazzo 6/17/2021 6/17/2021
General Manager NatalieUrner 9/1/2021 9/1/2021
Company Secretary KosmasDimitriou 1/13/2022 1/13/2022
Non-Executive Director TerenceRego 3/22/2021 3/22/2021
Non-independent Non-Executive Director ConTsigounis 46 6/22/2015 6/22/2015

General Information
Outstanding Shares: 130,680,980 (As of 6/30/2021)
Stock Exchange: ASX
Fax Number: +61 283629547


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 2, 2024